Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. 2 DOSAGE AND ADMINISTRATION
ثبت نشده
چکیده
----------------------WARNINGS AND PRECAUTIONS --------------------- Bone Marrow Suppression: Mea sure blood counts prior to treatment initiation and before every dose of Xofigo. Discontinu e Xofigo if hematologic values do not recover within 6 to 8 weeks after treatment. Monitor patients with compromised bone marrow reserve closely. Discontinue Xofigo in patients who experience life-threatening complications despite supportive care measures. (5.1)
منابع مشابه
Radium-223: the newest option in metastatic castration-resistant prostate cancer.
OS Radium-223 (Xofigo, Bayer and Algeta) is a boneseeking radiopharmaceutical that patients receive via injection. It is approved by the US Food and Drug Administration (FDA) to relieve pain and prolong survival in patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic evidence of bone metastasis. Because radium-223 selectively targets bone, it is not indicat...
متن کاملRadium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA review was based on clinical trial BC1-06, which randomly allocated patients ...
متن کاملCCR Perspectives in Drug Approval Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
OnMay15, 2013, theU.S. FoodandDrugAdministration (FDA) approved radiumRa223dichloride (Ra223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castrationresistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA reviewwas based on clinical trial BC1-06, which randomly allocated patients (2:1) to eit...
متن کاملCCR Perspectives in Drug Approval Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
On December 10, 2012, the U.S. Food and Drug Administration granted full approval for a modified indication for abiraterone acetate (Zytiga tablets; Janssen Biotech, Inc.) in combinationwith prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The approval was based on clinical trial COU-AA-302, which randomly allocated asymptomatic or mildly sy...
متن کاملAbiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
On December 10, 2012, the U.S. Food and Drug Administration granted full approval for a modified indication for abiraterone acetate (Zytiga tablets; Janssen Biotech, Inc.) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The approval was based on clinical trial COU-AA-302, which randomly allocated asymptomatic or mildly s...
متن کامل